key: cord-0858781-hwjh2bw7
authors: Kniepeiss, Daniela; Jantscher, Lydia; Al-Sharafy, Shahdy; Sendlhofer, Gerald; Schemmer, Peter
title: Framework for Solid-Organ Transplantation During COVID-19 Pandemic in Europe
date: 2021-06-04
journal: Risk Manag Healthc Policy
DOI: 10.2147/rmhp.s286721
sha: f05966169d395e115c803eb9701f7ef91f825d74
doc_id: 858781
cord_uid: hwjh2bw7

INTRODUCTION: Since the effect of the COVID-19 pandemic on solid-organ transplantation (SOT) is unclear, an online survey on the specific framework of leading European transplant centers (n=155) in 31 European countries was conducted between April 24 and May 15, 2020. METHODS: A questionnaire was designed to collect information on restrictions on SOT, protective measures,(non)governmental information policies, and individual opinions on how to deal with SOT during COVID-19. RESULTS: The response rate was 37.4% (58 of 155). Overall, 84.5% reported an effect of COVID-19 on SOT in Europe. In 49% of these, limited capacity was mentioned, and in 51% the reason for restricted resources was strategic preparedness. As a result, SOT was totally or partially suspended for several weeks. In sum, 93.1% of centers implemented protective measures against COVID-19. Nongovernmental information policies were felt to be adequate in 90%. Continuation of transplant activities was desired by 97% of centers. CONCLUSION: The results of this survey suggested a need for more ICU capacity during COVID-19, in order to guarantee adequate and timely treatment of other patient cohorts in surveyed countries.

Coronavirus type 2 is responsible for severe acute respiratory syndrome (SARS-CoV 2), as well as the associated COVID-19, which occurred first in Wuhan, China in December 2019. 1, 2 The virus spread around the world within a few weeks 2 and became a public-health emergency of international concern at the end of January 3 and a pandemic on March 11, 2020. 4 At that point, the number of new cases in Europe had gone beyond those in China, and cases were doubling (depending on the country) within a few days. 5 All countries within Europe had confirmed cases of COVID-19 patients and deaths. The most affected countries were Italy, Spain, France, and the UK. In order to prevent further spread of the virus, most European governments established lockdowns, including self-isolation, social distancing, closing schools, and banning of events, which affected >250 million people. 6 During 2020, lockdowns and further waves of the pandemic alternated and were a never-ending challenge for hospital management and politics. At the time of writing, more than 102 million confirmed COVID-19 cases and over 2 million deaths have been reported worldwide. 7 Due to the COVID-19 pandemic, new challenges for health-care systems in all countries have arisen and there has been uncompromising prioritization of capacity of hospital facilities and human resources toward COVID-19 patients. Depending on the severity of the wave of infections, there was also a shortage of resources by actual capacity (eg, Italy, Spain) 4, 5, 7 or by governmental and/or hospital policies in the sense of strategic preparedness (eg, Germany, Austria, Baltic states). In both cases, treatment was restricted for all other patient cohorts but emergencies. Surgical societies drew up lists of procedures that could be performed during the pandemic, including transplantations as life-saving procedures. 8 The impact of COVID-19 on solid-organ transplantation (SOT) was limited at the beginning of the pandemic [9] [10] [11] and is still unclear and controversial. [12] [13] [14] [15] [16] [17] [18] Furthermore, it is unknown whether it affects the donor pool or whether there is a risk of virus transmission during transplantation. In addition, the risk of infection of living donors and of possibly poorer outcomes for organ recipients is still not clear. Since there are no evidence-based guidelines to deal with COVID-19 and transplantation, many centers have considered restricting (urgency, risk stratification) or even stopping their activities. 11, 19, 20 To evaluate the framework for SOT in Europe during the first lockdown, we conducted an online survey between April 24 and May 15, 2020. A questionnaire to collect information on restrictions on SOT, protective measures, (non)governmental information policies, and individual opinion on how to deal with SOT during COVID-19 was designed.

The survey link was distributed between April 24 and May 15, 2020 by email to transplant surgeons at established centers (n=155) within 31 European countries. It was requested that the survey be filled out only once per center. Three reminders were automatically sent at weekly intervals to those who did not respond to the initial email. Only fully completed surveys were able to be returned.

This questionnaire on COVID-19 and SOT was created at the General, Visceral, and Transplant Surgery division, Medical University of Graz, Austria ( Figure 1 ). The survey comprised multiple-choice questions and yes/no questions. Depending on the answer in the latter, more detailed questions were asked.

The first part of the survey included general questions on location (country) of the transplant center, hospital size, represented by total beds (up to 500, up to 1,000, up to 1,500, up to 2,000, >2000), and both total intensive care unit (ICU) beds and intermediate-care unit (IMC) beds (up  to 20, up to 50, up to 100, up to 150, >150) .

Furthermore, specific data of transplant centers were evaluated including transplant dedicated capacity, ie, ICU/ IMC beds, (up to five, up to ten, up to 20, >20). Moreover, both number of transplantations per year (up to 25, up to 50, up to 100, >100) and number of transplant surgeons (up to five, up to ten, up to 20, >20) were asked about. There was a requirement to fill in the type of organ and the origin of grafts (deceased, living).

Data on the following topics were collected:

(I) Restrictions on SOT (questions 3.1-3.8): It was asked whether there had been an effect on the transplant program, and if yes, whether it was caused by shortage of resources or by hospital or governmental policies. In both cases, we intended to find out which resources were limited (beds, equipment, medication, staff) and whether there was a related impairment of the transplant program (same selection, but additionally "only for highly urgent or the sickest patients" in liver, kidney, heart, and lung transplantation 

(III) (Non)governmental information and policies (questions 4.1-4.10): These questions aimed to evaluate sufficiency of support with relevant information provided by local (hospital administration, physicians' chamber, governmental), national (governmental, physicians' chamber, societies, organprocurement organization), and international (governmental -European Union (EU), societies, organ-procurement organization) institutions. (IV) Personal opinion on how to deal with SOT during COVID-19 (questions 3.9, 5.1, 5.2): The main question was if transplant centers should continue their programs in general or based only on organ and/or urgency. If the latter of possibilities was answered with a "yes", the specific programs to be continued had to be selected.

The questionnaire was collected anonymously and data collected imported automatically and evaluated using the EvaSys program. 21 Data were displayed as descriptive statistics.

The response rate was 37.4% (58 of 155) of centers from 17 European countries ( Figure 2 

All kinds of SOT were represented in the survey ( Due to differeing severity of COVID-19 pandemic, health-care systems, and governments among European countries there was a certain heterogenity between countries concerning the impact on their transplant centers (Table 1) .

Respondents from Italy reported an effect of COVID-19 on transplant programs of 100% (50% shortage of resources and 50% hospital or governmental policies). In up to 25%, the entire transplant program had been stopped. In Austria, 60% of resources were limited by hospital and/or governmental policies, in Germany, this was only 22.7%. In Austria, the deceased kidney transplantation program had stopped in 100%, the living kidney program in 83.3%, the pediatric kidney program in 50%, and the pancreas program in 83.3%. In Germany, the deceased kidney transplantation program was continued, but the living kidney program was stopped in 80, and the pancreas transplantation program in 50%.

A total of 13.8% of transplant centers disagreed with current policies. However, in some European countries there agreement of only 50-60% with hospital or governmental policies concerning COVID-19 (Table 1) .

Most of the transplant centers (93.1%) implemented protective measures against COVID-19. Recipients were isolated in 64.8% of centers (single room in 71.4%, single room + airlock in 17.1%, single room + airlock + overpressure system in 11.4%). Visit bans were in place in 77.8%, and number of health care professionals at once with recipient had been restricted to two in 40.7% of centers. Further modified standards comprised wearing of masks for both recipient and health-care professionals (surgical mask 85%/ 83.3%, FFP2 mask 12.5%/14.6%, FFP3 mask 2.5%/ 2.1% of centers). Changes in immunosuppressive regimen were carried out in only 7.4%, and no changes in prophylactic medication with antibiotic, antimycotic, or antiviral therapy were reported. COVID-19 PCR testing of recipients was found in 93.1% and of donors in 94.8%. 

Respondents felt adequately informed about the topic by local (hospital administration 91.4%, physicians' chamber 77.6%, governmental 77.6% of centers), national (governmental 79.3%, physicians' chamber 75.9%, societies 86.2%, organ-procurement organizations 75.9% of centers), and international (governmental -EU 56.9%, societies 79.3%, organ-procurement organizations 60.3% of centers) information policies.

Of all transplant centers, 96.6% would continue transplant activity in general (52%) during COVID-19 or based on organ and/or urgency (48%).

Survey results demonstrated a tremendous impact of COVID-19 on transplant centers in Europe. Related impairment of transplant activity was caused either by actual shortage of resources or strategic preparedness, given by hospital/governmental policies. Both reasons for restrictions were present to the same extent. Actual impairment by number, however, remains unclear. This is the first assessment of the impact of COVID-19 on SOT in Europe. Other surveys that have been carried out recently 22-28 focused on different topics and were carried out onlywithin one or a few countries. A survey with similar question was carried out in the US. 29 This survey may be the basis for speculating on the shortage of ICU capacity needed to provide health-care support for both COVID-19 and all other patients in most countries.

At the height of the pandemic, several European countries were affected by total utilization of the capacity of their health systems (eg, Italy, Spain, and France). 5,7 Both restrictions and even suspension of transplant programs were not Table 2) in various corresponding countries (eg, Germany). The characteristics of the health-care systems and the sociodemographic needs of the different European countries vary widely, and the measures recommended by the WHO have been applied differently across different countries and regions. During the pandemic, such countries as Germany, which have more ICU beds per head of population (Table 2) , were able to help other European nations that were temporarily or continuously overwhelmed with an excess of cases (eg, Italy). In Italy, ICUs had to be expanded and new hospitals built to cope with the demands of the escalating number of COVID-19 patients. Furthermore, human resources were reorganized and retired professionals and DovePress volunteers sent to hospitals in critical areas. In this situation, other patients, such as cancer or transplant patients, could no longer be cared for, due to lack of resources, above all limited beds, staff, and equipment. As for our survey, transplant centers in Italy were affected 100% (50% by shortage of resources and 50% by hospital or governmental policies). In up to 25%, whole transplant centers were closed. However, 25% of the responding centers did not agree with health-care policy. All the queried centers would have liked to continue their transplant activity during COVID-19 (52% in general, 48% based on organ and/or urgency) in order to be able to continue caring for their patients. US data comparable to those from Italy were published recently. 29 Results of a nationwide survey demonstrated complete suspension rates of living kidney transplantation in up to 71.8% and living liver transplantation in up to 67.7%. Restrictions of deceased kidney-transplantation programs were declared in 84% and of deceased liver-transplant programs in 73.3%. Almost no restrictions were placed on heart-or lungtransplantation programs. A completely different situation was observed in other European countries, where the severity of the COVID-19 pandemic was not that substantial. In order to be prepared for a possibly extreme COVID-19 situation, resources were kept free for safety reasons and thus restricted. Strategically prepared countries were Austria and Germany, for example, but interestingly there were differences between them. While in Austria, 60% of resources were limited by hospital and/or governmental policy, in Germany it was only 22.7%. In Austria, the deceased kidney-transplantation program was 100% stopped, while in Germany it was continued. While transplant centers in Germany mostly agreed with hospital or governmental policies, in Austria there was disagreement of 40%. Almost all transplant centers in both countries (Austria 100%, Germany 95.5%) agreed to continue transplantation during COVID-19 in general (Austria 30%, Germany 66.6%) or based on organ and/or urgency (Austria 70%, Germany 33.3%).

Our results showed that the resources of all transplant centers in Europe were more or less affected by COVID-19. The extent of the negative effect on transplantation depended on the severity of the infection wave, but also on strategic measures within individual countries. An important goal for the future must be to learn from the experiences of all countries and develop strategies for the future that can support a reduction in the collateral damage of pandemics on transplant centers. [30] [31] [32] It must be clear that a dramatic increase in patients requires an increase in resources, unless restrictions treating patients with ICU/ IMC requirements in need of isolation are accepted.

Another approach to continuing SOT is restriction of treatment to highly selected patients. As an example, the sickest-first strategy could be applied. As an alternative, the healthiest patients are treated on the assumption of better resistance against COVID-19 infection and thus better survival after transplantation. Data from this survey clearly showed that up to 33.3% of the centers transplanted only highly urgent or the sickest patients. Deceased and pediatric programs should be continued over living transplant programs. However, transplanting only healthier recipients with the best-quality organs and lowest risk of delayed graft function might also be a good strategy. 29 When trying to select, some criteria might be considered: kidney transplantation, preemptive transplantation, highly sensitized patients, those with negative cross matching, or higher-acuity patients. In cases of liver transplantation, patients could be stratified on the severity of their illness, first transplants, and those with tumors without other options. For heart and lung transplantation as lifesaving procedures, there were almost no restrictions and there should not be any in future. In any case, COVID-19 recipient-and donor-testing availability is mandatory, and attention should be paid to a low-risk COVID-19 setting (both donor and recipient SARS-CoV2-negative).

In the middle of March 2020, when the COVID-19 pandemic started, knowledge on the impact of the virus in a transplant setting including immunosuppression was scarce and discouraging. 19, 33, 34 Therefore, some transplant centers considered stopping their programs 11, 12, 20 or restricting transplantation to highly urgent or riskstratified patients. Risk stratification was especially difficult, due to pending data or even scores. During the following weeks, many recommendations from transplantation or surgical societies, clinical studies, and case reports were published, 35 In our center, liver transplantation was safely performed during COVID-19 in a low-risk setting (both donor and recipient SARS-CoV2--negative, low disease-severity recipients [labMELD score <25], and a low donor risk-index graft). 41 However, data concerning the impact of COVID-19 on patients after transplantation are still rare and controversial; therefore, we urgently need data from further studies that could provide important information for the care of transplant recipients.

This is the first survey to give an overview of 58 transplant centers within 17 European countries and their framework for SOT during the COVID-19 pandemic. Results of this survey suggest a desperate need for ICU capacity during COVID-19 in most countries to guarantee adequate and timely treatment of other patient cohorts.

Risk Management and Healthcare Policy is an international, peerreviewed, open access journal focusing on all aspects of public health, policy, and preventative measures to promote good health and improve morbidity and mortality in the population. The journal welcomes submitted papers covering original research, basic science, clinical & epidemiological studies, reviews and evaluations, guidelines, expert opinion and commentary, case reports and extended reports. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors. 

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV). World Health Organization (WHO)

WHO Director-General's opening remarks at the media briefing on COVID-19-11

COVID-19) -research and statistics. Wayback Machine

More than 250m in lockdown in EU as Belgium and Germany adopt measures. The Guardian

WHO Coronavirus (COVID-19) Dashboard. Available from: https:// covid19.who.int

COVID-19 in kidney transplant recipients

Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression

Coronavirus disease 2019: implications of emerging infections for transplantation

Coronavirus disease-19: disease severity and outcomes of solid organ transplant recipients: different spectrums of disease in different populations?

Covid-19 and kidney transplantation

COVID-19 in kidney transplant recipients

Early description of coronavirus 2019 disease in kidney transplant recipients in New York

COVID-19 in solid organ transplantation patients: a systematic review

COVID-19 in solid organ transplant recipients: initial report from the US epicenter

COVID-19 in solid organ transplant recipients: a single-center experience

COVID-19: a global transplant perspective on successfully navigating a pandemic

Coronavirus disease 2019 and transplantation: a view from the inside

Pediatric transplantation in Europe during the COVID-19 pandemic: early impact on activity and healthcare

COVID-19 and kidney transplantation: an Italian survey and consensus

Survey of US living kidney donation and transplantation practices in the COVID-19 era

COVID-19 among heart transplant recipients in Germany: a multicenter survey

Management of lung transplantation in the COVID-19 era -An international survey

Impact of COVID-19 on lung transplant activity in germany-a cross-sectional survey

COVID-19 lockdown: impact on liver transplant recipients-a single centre survey

Early impact of COVID-19 on transplant center practices and policies in the United States

How should U.S. hospitals prepare for coronavirus disease 2019 (COVID-19)?

Thinking of treatment strategies for colorectal cancer patients in tumor hospitals under the background of coronavirus pneumonia

Establishing and managing a temporary coronavirus disease 2019 specialty hospital inWuhan

Fatal outcome in a liver transplant recipient with COVID-19

MERS CoV infection in two renal transplant recipients: case report

Clinical best practice advice for hepatology and liver transplant providers during the COVID-19 pandemic: AASLD expert panel consensus statement

COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy

Recovery from COVID-19 following hepatitis C, human immunodeficiency virus infection and liver transplantation

Kidney transplant programmes during the COVID-19 pandemic

Challenges and countermeasures for organ donation during the SARS-CoV-2 epidemic: the experience of Sichuan Provincial People's Hospital

The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy

Characteristics associated with liver graft failure: the concept of a donor risk index

We especially thank all responding transplant centers for their kind participation.

All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data, took part in drafting the article or revising it critically for important intellectual content, agreed to submit to the current journal, gave final approval to the version to be published, and agree to be accountable for all aspects of the work.

The authors of this manuscript have no conflicts of interest to disclose.